Transasia Bio-Medicals opens talks to sell 20% stake for $150-200M
Transasia Bio-Medicals, a Mumbai-based diagnostics manufacturer, has opened talks to sell up to 20% of its stake for $150-200 million. This is the company’s first attempt to raise external capital. Five major private equity funds, including TPG and Warburg Pincus, are already in early discussions.
Editor, Lazyfounder

30 SEC SUMMARY
- Transasia Bio-Medicals is in early talks to sell up to 20% of its stake for $150-200 million, marking its first external fundraising.
- Five major private equity funds, including TPG and Warburg Pincus, have expressed interest in the deal.
- The company, a leader in India’s in-vitro diagnostics sector, operates in 150 countries and is part of the Erba group.
- India’s medtech market, valued at $12 billion in FY24, is projected to grow to $50 billion by 2030.
- The deal could combine fresh capital for growth with partial exits for early shareholders, including founder Suresh Vazirani.
TABLE OF CONTENTS
First external fundraise draws five PE funds
Mumbai-based Transasia Bio-Medicals has started talks to sell up to 20% of its equity for $150-200 million. This marks the company’s first attempt to raise external capital. O3 Capital is advising the deal, which has drawn interest from five private equity funds: TPG, Warburg Pincus, ChrysCapital, Motilal Oswal and Quadria Capital.
Deal structure balances growth and liquidity
The deal is likely to mix fresh capital for growth with a secondary sale allowing early shareholders, including founder Suresh Vazirani, to cash out part of their holdings. The exact split will depend on which investor comes on board.
From importer to global diagnostics leader
Transasia Bio-Medicals began in 1979 when Suresh Vazirani set it up to fill gaps in India’s medical-equipment market. It started as a distributor of imported devices but soon shifted to local manufacturing.
Today, the company is part of the Erba group and operates in 150 countries. It runs five factories in India, the Czech Republic and Russia, and maintains three R&D centers. Its product range covers biochemistry, hematology, immunology, critical care, diabetes management and molecular diagnostics, making it one of India’s largest in-vitro diagnostics players. Competitors include Tulip Diagnostics, Accurex Biomedical, Trivitron Healthcare and global firms like Roche Diagnostics.
India’s medtech market poised for growth
India’s medtech market reached $12 billion in fiscal 2024 and is projected to grow to $50 billion by 2030, according to industry estimates. Rising incomes, wider health insurance coverage and medical tourism are pushing demand for both affordable and high-end devices, especially in smaller cities.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
A successful $150-200 million raise would set the first benchmark valuation for India’s in-vitro diagnostics sector, giving competitors and investors a reference point for future deals.
Key takeaways
- This sale could trigger a wave of fundraising or consolidation among India’s diagnostics firms as they prepare for a $50 billion medtech market by 2030.
- Founder Suresh Vazirani is using the deal to secure partial liquidity while keeping control of the company.
- Early interest from global PE funds shows India’s medtech sector is now on the radar of large institutional investors.
Related on Lazyfounder
Sources
- Mint (Technology) · 2026-11-16
Transasia BioMedicals explores up to 20% stake sale to raise $200 million
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.


